# Triple Therapy Versus Levofloxacin-based Therapy for Helicobacter Pylori Eradication in Mexico.

> **NCT02726269** · PHASE3 · COMPLETED · sponsor: **Asofarma de México S.A de C.V.** · enrollment: 230 (actual)

## Conditions studied

- Helicobacter Pylori Gastritis

## Interventions

- **DRUG:** CLA (Clarithro+Lanso+Amoxi)
- **DRUG:** PLA (Panto+Levoflox+Azithro)

## Key facts

- **NCT ID:** NCT02726269
- **Lead sponsor:** Asofarma de México S.A de C.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06
- **Primary completion:** 2014-03
- **Final completion:** 2014-05
- **Target enrollment:** 230 (ACTUAL)
- **Last updated:** 2016-04-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02726269

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02726269, "Triple Therapy Versus Levofloxacin-based Therapy for Helicobacter Pylori Eradication in Mexico.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02726269. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*